<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03122925</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00000143</org_study_id>
    <nct_id>NCT03122925</nct_id>
  </id_info>
  <brief_title>TCA Cycle in the Dentate in Friedreich's Ataxia</brief_title>
  <official_title>Measurement of the TCA Cycle Rate in the Dentate Nucleus in Friedreich's Ataxia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota - Clinical and Translational Science Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Minnesota - Clinical and Translational Science Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      OBJECTIVE: To measure the tricarboxylic acid (TCA) cycle rate in the dentate nucleus in a
      group of control subjects and subjects with Friedreich's Ataxia (FRDA).

      HYPOTHESIS: The TCA cycle rate will be lower in FRDA subjects than in controls APPROACH: The
      investigators will infuse carbon-13 (13C) labeled glucose and measure the rate of 13C label
      incorporation from glucose to glutamate in the brain using in vivo magnetic resonance
      spectroscopy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will measure the TCA cycle rate in the dentate nucleus in a group of FRDA
      patients and in a group of age-matched healthy controls using 13C MRS in vivo together with
      systemic i.v. infusion of 13C-labeled glucose.

      The investigators aim to obtain adequate data in 16 subjects grouped as follows:

        -  n=4 pilot subjects (healthy subjects) for testing and optimization of the experimental
           setup.

        -  n=6 healthy controls

        -  n=6 FRDA patients

      In other to reach this goal, the investigators plan to recruit up to 20 subjects, in case
      some subjects withdraw before completion of the MR scan, or in case the measured data are not
      adequate (e.g. technical problem with the scanner).
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">August 15, 2017</start_date>
  <completion_date type="Anticipated">July 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>TCA cycle rate in the dentate nucleus</measure>
    <time_frame>Baseline</time_frame>
    <description>value between 0 to 2 micromol/g/min</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Friedreich Ataxia</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Healthy subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Friedreich's Ataxia</arm_group_label>
    <description>Diagnosed for Friedreich's Ataxia</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MR</intervention_name>
    <description>MR</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Friedreich's Ataxia</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy controls Friedreich's Ataxia diagnosis
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age or older

          -  able to consent for themselves

          -  considered healthy (controls) OR be diagnosed with FRDA.

        Exclusion Criteria:

          -  All subjects:

          -  Participants who cannot have an MRI, as determined by the CMRR safety screening form
             (e.g. metal implant)

          -  Pregnancy

          -  Clautrophobia

          -  Diabetes

          -  Clinically significant cardiac disease

        Control subjects:

        - Neurological disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre-Gilles Henry, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota - Clinical and Translational Science Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CMRR</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2017</study_first_submitted>
  <study_first_submitted_qc>April 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2017</study_first_posted>
  <last_update_submitted>August 24, 2017</last_update_submitted>
  <last_update_submitted_qc>August 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ataxia</mesh_term>
    <mesh_term>Cerebellar Ataxia</mesh_term>
    <mesh_term>Friedreich Ataxia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

